Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
Clinical trial NCT02593773 · COMPLETED
Trial details
- NCT number
- NCT02593773
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-25
- Primary completion
- 2017-03-21
- Enrollment
- 86
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.